AstraZeneca Vaccine Linked With Small Risk Of Low Blood Platelets: Study.

AstraZeneca COVID-19 Vaccine Linked With Small Risk Of Low Blood Platelets: Study

The Oxford-AstraZeneca vaccine is also known as the Covishield vaccine

London:

The Oxford-AstraZeneca vaccine, also known as Covishield, may be associated with a very small risk of developing a blood condition characterised by low platelet counts, according to a nationwide study in the UK.

The increased risk of the condition, known as idiopathic thrombocytopenic purpura (ITP), is estimated to be 11 per million doses, similar to figures seen in vaccines for flu, and measles, mumps, and rubella (MMR), the researchers said.

A low number of platelets -- blood cells that help prevent blood loss when vessels are damaged -- can result in no symptoms or can lead to an increased risk of bleeding or, in some cases, clotting, they said.

The team, led by researchers at the University of Edinburgh in the UK, noted that people at most risk from ITP tended to be older -- a median age of 69 years old -- and had at least one underlying chronic health problem such as coronary heart disease, diabetes or chronic kidney disease.

The researchers were unable to establish a definitive link between other forms of clotting -- including the rare form called cerebral venous sinus thrombosis or CVST -- due to the very low number of cases in vaccinated people included in the study.

The study of 5.4 million people in Scotland, of whom 2.5 million had received their first vaccine dose, is the first analysis of ITP, clotting and bleeding events following vaccination for an entire country.

The authors of the study, published in the journal Nature Medicine on Wednesday, emphasised that the increased chance of developing ITP after receiving the vaccine remains smaller than the risk of developing it because of COVID-19.

They noted that the rare risk should not deter the roll out of the vaccine programme.

The same risk of ITP was not found for the Pfizer-BioNTech vaccine. Other vaccines were not included in the study.

The researchers analysed a dataset as part of the EAVE II project, which uses anonymised linked patient data to track the pandemic and the vaccine roll out in real time.

They investigated data up to April 14, 2021 for people in Scotland who had received the first dose of either vaccine.

By this date, over 1.7 million had an Oxford-AstraZeneca jab and some 800,000 had a dose of the Pfizer-BioNTech vaccine.

Experts recommend that recipients of the Oxford-AstraZeneca vaccine should be made aware of the slight increased risks of ITP, but also stress that the risk of developing these disorders from COVID-19 is potentially much higher.

UK's Medical and Healthcare products Regulatory Agency (MHRA) had previous reported low platelet counts in combination with blood clots following vaccination with the AstraZeneca vaccine, estimated to occur at a rate of approximately 13 per million first doses.

The researchers, including those from the universities of Strathclyde, Aberdeen, Glasgow, Oxford, Swansea and St Andrew's, also looked at health records dating back to September 2019 to investigate any previous issues with ITP, clotting or bleeding disorders.

The data was then compared with those who were yet to be vaccinated to determine if any clotting events were outside what would have been expected pre-pandemic.

The analysis indicated that there was a slight increase in ITP in the second week following vaccination for those who received the AstraZeneca vaccine and possibly also increased risk of arterial clotting and bleeding events.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news
Byron Donalds responds to 'tense' interview with CNN anchor.

Byron Donalds responds to 'tense' interview with CNN anchor.

Florida Rep. Byron Donalds responds to being shut out of the Congressional Black Caucus for allegedly holding conservative values. #FoxNews Subscribe to Fox News! Watch more Fox News Video: Watch Fox News Channel Live: FOX News Channel (FNC) is a ...

1 222

G7: How Cornwall is leading the green revolution

G7: How Cornwall is leading the green revolution

World leaders want to make climate change one of the priorities of the G7 summit and Cornwall is considered to be a fitting location. The English county is leading the way for clean energy - with wind, solar and even geothermal projects all based ...

Fruit Vendors Feed 1,000 Hungry Monkeys Amid Lockdown in India.

Fruit Vendors Feed 1,000 Hungry Monkeys Amid Lockdown in India.

Fruit vendors in India's southern Tamil Nadu state are comforting about 1,000 hungry monkeys at a temple there by feeding them during the ongoing lockdown imposed to curb the spread of coronavirus. As the famous Thiruparankundram Murugan Temple in...

Royals launch charm offensive at G7 summit

Royals launch charm offensive at G7 summit

The Queen was joined by senior members of the Royal Family as they aimed to boost Britain's profile on the world stage. SUBSCRIBE to our YouTube channel for more videos: Follow us on Twitter: Like us on Facebook: Follow us on Instagram: For more c...

Gutfeld: CNN becomes more 'racist' everyday, they are in freefall.

Gutfeld: CNN becomes more 'racist' everyday, they are in freefall.

'The Five' reacts to CNN host Brianna Keilar sparring with Rep. Byron Donalds over Congressional Black Caucus snub. #FoxNews #TheFive Subscribe to Fox News! Watch more Fox News Video: Watch Fox News Channel Live: FOX News Channel (FNC) is a 24-hou...

Press Preview: What’s making Saturday’s front pages?.

Press Preview: What’s making Saturday’s front pages?.

We take a look at what’s making the news on Saturday with Christina Lamb, the Sunday Times' chief foreign correspondent, and conservative commentator Tim Montgomerie. SUBSCRIBE to our YouTube channel for more videos: Follow us on Twitter: Like us ...